-
Jan 5, 2025 | 
jnnp.bmj.com | Mirthe Coenen |Xin Xu |Saima Hilal |Frederik Barkhof
X @MarcoDueringJMB and CHT contributed equally. Collaborators Alzheimer’s Disease Neuroimaging Initiative: data used in the preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (https://adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in the analysis or writing of this report.
-
Nov 26, 2024 | 
alzres.biomedcentral.com | Antti Tolonen |Frederik Barkhof |Juha Koikkalainen |Sanna-Kaisa Herukka |Steen Gregers Hasselbalch |Patrizia Mecocci | +4 more
In an era where disease-modifying therapies are becoming available for the first time, timely and accurate diagnosis of dementia is more important than ever. A data-driven tool can be beneficial for assisting clinicians in determining which tests add value in different clinical contexts. In this study, we applied a data-driven stepwise testing approach using a CDSS in three clinical scenarios to assess its potential to guide diagnostic decision-making.
-
Oct 12, 2024 | 
alzres.biomedcentral.com | Anna Svenningsson |Diana I. Bocancea |Erik Stomrud |Frederik Barkhof |Niklas Mattsson-Carlgren |Sebastian Palmqvist | +3 more
-
Sep 3, 2024 | 
nature.com | Ruth Geraldes |Georgina Arrambide |Alex Rovira |Hans Lassmann |Patrick Waters |Declan T. Chard | +6 more
AbstractMyelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is an immune-mediated demyelinating disease that is challenging to differentiate from multiple sclerosis (MS), as the clinical phenotypes overlap, and people with MOGAD can fulfil the current MRI-based diagnostic criteria for MS. In addition, the MOG antibody assays that are an essential component of MOGAD diagnosis are not standardized.
-
Jun 14, 2024 | 
nature.com | Sophie E Mastenbroek |Jacob Vogel |Lyduine E. Collij |Alexandra Young |Frederik Barkhof |Rik Ossenkoppele
AbstractLewy body (LB) diseases, characterized by the aggregation of misfolded α-synuclein proteins, exhibit notable clinical heterogeneity. This may be due to variations in accumulation patterns of LB neuropathology. Here we apply a data-driven disease progression model to regional neuropathological LB density scores from 814 brain donors with Lewy pathology.
-
Jun 13, 2024 | 
journals.sagepub.com | Eva A. Krijnen |Samantha Noteboom |Frederik Barkhof |Rose-Marie Kouwenhoven
Get full access to this articleView all access and purchase options for this article. Data availability statementThe tabulated data that support our findings are available from the corresponding author, upon reasonable request. References1. Sumowski JF, Benedict R, Enzinger C, et al. Cognition in multiple sclerosis: State of the field and priorities for the future. Neurology 2018; 90(6): 278–288. 2. Ziccardi S, Pisani AI, Schiavi GM, et al.
-
Apr 14, 2024 | 
journals.sagepub.com | Ahmed Toosy |Frederik Barkhof
Currently, the diagnosis of multiple sclerosis (MS) requires two conditions: dissemination in space (DIS) and dissemination in time (DIT), but only after a demyelinating clinical episode.
-
Mar 23, 2024 | 
onlinelibrary.wiley.com | Mario Tranfa |Alessandra Scaravilli |Frederik Barkhof |Alfredo Montella
Patients with Fabry disease show significantly higher brain-predicted age difference values compared to healthy controls (estimated marginal means: 3.1 vs. −0.1, p = .01). Brain-predicted age difference correlates with multi-organ disease severity and is associated with brain parenchymal fraction, white matter hyperintensities load, and tissue volume throughout the brain.
-
Feb 26, 2024 | 00036-6/abstract?rss=yes&sz=64)
thelancet.com | Frederik Barkhof |Biomedical Engineering |Geoff Parker
The diagnosis and management of patients with brain tumours such as glioma relies heavily on the use of MRI. Patients with brain tumours typically undergo multiple MRI scans for diagnosis, surgical planning, and monitoring of chemotherapy or radiotherapy.
-
Jan 8, 2024 | 
nature.com | Betty M. Tijms |Henne Holstege |Lisa Vermunt |Niccolò Tesi |Eugeen Vanmechelen |Frederik Barkhof | +1 more
AbstractAlzheimer’s disease (AD) is heterogenous at the molecular level. Understanding this heterogeneity is critical for AD drug development. Here we define AD molecular subtypes using mass spectrometry proteomics in cerebrospinal fluid, based on 1,058 proteins, with different levels in individuals with AD (n = 419) compared to controls (n = 187).
